Strengthening Business Development and Licensing Operations Leveraging Proprietary Technologies
First written in FY2016. 18 of 26 entries say "Advanced", first in FY2017. Latest entry: FY2026.
2 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「As a result of actively pursuing the out-licensing of newly created technologies and research programs, the company concluded license agreements with multiple pharmaceutical companies in fiscal 2025.」
Regarding out-licensing activities for proprietary technologies and research programs, the company progressed to concluding agreements with multiple pharmaceutical companies in fiscal 2025. Specific transactions included the out-licensing of JUST-AAV to Alexion and a J-Brain Cargo® license option agreement with Acumen. - FY2025AdvancedAnnual report
「The company began joint research with MODALIS in December 2023 to develop a novel gene therapy using this technology. In January 2025, it concluded a new joint research agreement after achieving validation of the initial technical concept in the joint research.」
The joint research with MODALIS on a novel gene therapy applying J-Brain Cargo® achieved validation of the initial technical concept and progressed to the conclusion of a new joint research agreement. - FY2025-H1AdvancedAnnual report
「For this product, the policy is to advance development through an out-licensing arrangement rather than in-house development, and negotiations are under way with prospective partners regarding the license.」
Regarding licensing of proprietary technologies and development products, the company decided to advance JR-171 through out-licensing rather than in-house development and made the out-licensing negotiations more concrete. - FY2024AdvancedAnnual report
「Research progressed smoothly, and the company achieved the first milestone for the neurodegenerative disease treatment in March 2024.」
The joint research with Alexion on a neurodegenerative disease treatment applying J-Brain Cargo® achieved its first research-stage milestone in March 2024. - FY2024-Q3AdvancedAnnual report
「In December 2023, the company concluded a joint research, option and license agreement with Alexion AstraZeneca Rare Disease (Alexion) for the discovery of novel nucleic acid medicines applying J-Brain Cargo® technology. This was the second partnership with Alexion, following the joint research, option and license agreement concerning a treatment for neurodegenerative diseases applying J-Brain Cargo® technology concluded in March 2023.」
Regarding business development and licensing using its proprietary technologies, the agreement with Alexion became the company's second partnership following the neurodegenerative disease treatment, broadening the target modality to nucleic acid drug discovery. - FY2024-Q2AdvancedAnnual report
「In September 2023, the company concluded a license agreement with Medipal Holdings Corporation for commercialization outside Japan, as well as a joint development and commercialization agreement in Japan.」
Regarding business development and licensing of proprietary technologies and development products, the company concluded an agreement with Medipal Holdings for the overseas license and the joint development and commercialization in Japan of JR-446. - FY2024-Q1AdvancedAnnual report
「In May 2023, the company concluded an exclusive global development and commercialization agreement with Angelini Pharma for a novel biologic applying J-Brain Cargo® technology to epilepsy.」
The company concluded an exclusive global development and commercialization agreement with Angelini Pharma for a novel biologic applying its J-Brain Cargo® technology, adding a specific example of business development and licensing expansion. - FY2023AdvancedAnnual report
「For the fucosidosis treatment (development code: JR-471), under the license agreement concluded in October 2022, the company granted Medipal Holdings Corporation an exclusive license with sublicensing rights for commercialization activities, including research and development, manufacturing and sales, worldwide excluding Japan. As the company that created this treatment, it will participate as the licensor and contribute to its early commercialization.」
For JR-471, the exclusive license covering the worldwide territory excluding Japan was granted to Medipal Holdings, adding a specific example of the company participating in commercialization as the licensor. - FY2023-Q3AdvancedAnnual report
「For the fucosidosis treatment (development code: JR-471), under the license agreement concluded in October 2022, the company granted Medipal Holdings Corporation an exclusive license with sublicensing rights for commercialization activities, including research and development, manufacturing and sales, worldwide excluding Japan. As the company that created this treatment, it will participate as the licensor and contribute to its early commercialization.」
For JR-471, the company granted Medipal Holdings an exclusive license covering research and development, manufacturing, sales and other activities worldwide excluding Japan. This added a specific example of the company participating in early commercialization as the licensor. - FY2022AdvancedAnnual report
「For Izcargo®, the company concluded an exclusive joint development and license agreement with Takeda Pharmaceutical Company Limited covering specified territories in September 2021. In March 2022, it also concluded an agreement with Takeda Pharmaceutical Company Limited for joint research into gene therapy using the company's proprietary J-Brain Cargo® technology.」
In addition to the exclusive joint development and license agreement with Takeda Pharmaceutical Company Limited for JR-141 in specified territories, the company concluded a joint research agreement for gene therapy using J-Brain Cargo®. - FY2022-Q2AdvancedAnnual report
「In September 2021, the company concluded an agreement with Takeda Pharmaceutical Company Limited for the joint development and commercialization of the next-generation Hunter syndrome treatment JR-141 in specified territories. This agreement enabled the Group to take another step forward as a global specialty pharmaceutical company.」
For JR-141, the company concluded an agreement with Takeda Pharmaceutical Company Limited for joint development and commercialization in specified territories, adding a specific partnership in licensing and business development. - FY2021SoftenedAnnual report
「The company terminated the joint development covered by the following agreement during the current consolidated fiscal year, based on an agreement between the two companies.」
The joint development with Aska Pharmaceutical Co., Ltd. concerning an infertility treatment product, recombinant follicle-stimulating hormone, was terminated by agreement between the two companies. - FY2021-Q3SoftenedAnnual report
「Contract revenue from the agreement concerning the out-licensing of the enzyme replacement therapy for lysosomal diseases has been pushed back to the consolidated accounting period for the fourth quarter.」
The timing of the out-licensing agreement for the enzyme replacement therapy for lysosomal diseases and recognition of the related contract revenue was pushed back again, from the expected third quarter to the fourth quarter. - FY2021-Q2SoftenedAnnual report
「The decline in contract revenue was attributable to the fact that the agreement concerning the out-licensing of enzyme replacement therapy products for lysosomal diseases was not finalized by the end of September, partly because the spread of COVID-19 made face-to-face negotiations difficult. As a result, the contract revenue expected in the cumulative consolidated period through the second quarter was pushed back to the consolidated accounting period from the third quarter onward.」
The out-licensing agreement for the enzyme replacement therapy for lysosomal diseases was not finalized by the end of September, pushing the planned contract revenue into the third quarter and beyond. - FY2020-Q2AdvancedAnnual report
「JR-041 (recombinant follicle-stimulating hormone) | Phase I/II clinical trial | Infertility treatment | Out-licensed to Aska Pharmaceutical Co., Ltd.」
The development status list explicitly identified JR-041 as having been out-licensed to Aska Pharmaceutical Co., Ltd., adding a specific example of product out-licensing. - FY2020-Q1RestatedAnnual report
「In addition, in terms of technology, the company established manufacturing technology for gene therapy products and will promote the development of new drugs and expansion of its licensing business together with its blood-brain barrier-penetrating technology, J-Brain Cargo®.」
The company reaffirmed its policy of applying gene therapy product manufacturing technology and J-Brain Cargo® to new drug development and its licensing business. - FY2019RestatedAnnual report
「The company also established manufacturing technology for gene therapy products and will promote the development of new drugs and expansion of its licensing business together with its blood-brain barrier-penetrating technology, J-Brain Cargo®.」
The company reaffirmed its policy of applying proprietary technologies such as J-Brain Cargo® to new drug development and its licensing business. The establishment of manufacturing technology for gene therapy products is being developed separately as a new technology platform. - FY2018AdvancedAnnual report
「The joint research with Dainippon Sumitomo Pharma Co., Ltd., with which the company concluded a feasibility study agreement in June 2015, produced favorable results and progressed to the conclusion of a license agreement in February 2018.」
The joint research concerning J-Brain Cargo® with Dainippon Sumitomo Pharma progressed to the conclusion of a license agreement in February 2018. - FY2018-Q2AdvancedAnnual report
「On 18 July of this year, the company concluded a joint development agreement and license agreement with Teijin Limited for a regenerative medical product for acute ischemic stroke using allogeneic (homologous) dental pulp-derived stem cells (DPC) (development code: JTR-161).」
As a specific example of its licensing business, the company concluded a joint development and license agreement with Teijin Limited for JTR-161. - FY2018-Q1AdvancedAnnual report
「As part of its licensing business, the company pursued negotiations with Teijin Limited to conclude a joint development agreement and license agreement for a regenerative medical product for acute ischemic stroke using allogeneic (homologous) dental pulp-derived stem cells (DPC) (development code: JTR-161).」
In its licensing business involving proprietary technologies and research results, the company pursued negotiations with Teijin Limited for a joint development and license agreement for JTR-161. - FY2017AdvancedAnnual report
「In addition to overseas expansion of the company's breakthrough drug candidates JR-141 and JR-162, which apply its proprietary J-Brain Cargo® technology, the technology itself may serve as a platform technology applicable to a broad range of drug candidates targeting central nervous system diseases. The company will actively pursue out-licensing negotiations. It is currently discussing potential out-licensing with several companies and believes that the technology can be licensed to many more companies in the future, so it will accelerate negotiations.」
In addition to applying J-Brain Cargo® to drug candidates, the company indicated that it is discussing out-licensing the technology itself with several companies and intends to accelerate negotiations. - FY2017-Q3RestatedAnnual report
「Against this backdrop, based on the five-year medium-term management plan “Hiyaku” formulated in the previous fiscal year, the Group worked to promote sales of its core products and expand its licensing business by leveraging its proprietary technologies.」
The company continues to promote its licensing business using its proprietary technologies. - FY2017-Q1RestatedAnnual report
「Against this backdrop, based on the five-year medium-term management plan “Hiyaku” formulated last year, the Group worked to promote sales of its core products and expand its licensing business by leveraging its proprietary technologies.」
The company continued to promote its licensing business using its proprietary technologies during the quarter as an initiative under its medium-term management plan. - FY2016First statedAnnual report
「The company implemented organizational reforms aimed at promoting sales of its core products and strengthening business development and licensing activities using its proprietary technologies.」
The company indicated its intention to use its proprietary technologies not only for product development but also to grant licenses to external parties.